Discussion Participants
Managing Director, Credit Advisory
About this Event
For life science companies, valuing an early stage product or pipeline is uniquely challenging. It requires detailed analysis and thoughtful forecasting of the potential of your product. Understanding the phase-by-phase risk your company will face is essential to determining the valuation of your early stage product or pipeline.
In this session, we will knit these key elements together to better understand valuations today and through each valuation inflection point.
Valuing Early Stage Life Science Companies to Optimize Partnership and Other Transactions
This Event concluded on:
March 27, 2025 - 1:00PM to 2:00PM ET
Event Resources:
These resources are for RBCx clients only, please sign in.
You must enable security cookies. This ensures your Marketplace session is secure.
Not an RBCx client? Talk to an RBCx Advisor.